DiaSorin offers free DNA extraction kits during February

Thursday, 16 January, 2014

DiaSorin is making a special offer for scientists involved in the clinical diagnosis or R&D of products for colon cancer and gastrointestinal diseases. With each DiaSorin Liaison Ixt/Arrow instrument purchased during February 2014, the company is providing over $3000 worth of LIAISON Ixt/Arrow Stool DNA extraction kits free of charge.

Analysis of DNA from stool samples may be required to identify viral or bacterial pathogens shed in faeces. Analysis of genomic DNA in human stools is also a new approach for the detection of colon cancer. In addition to purifying viral and bacterial DNA, the LIAISON Ixt/Arrow Stool DNA kits have been validated for the extraction of human DNA from human stool samples and are used for detection of gastrointestinal disease such as Clostridium difficile, Helicobacter pylori, rotavirus and Enterohaemorrhagic Escherichia coli (EHEC).

The consistent extraction of purified DNA from stool samples is difficult due to the complex and variable composition of faeces and the presence of high levels of PCR inhibitors in this matrix. The extraction kits overcome this problem by utilising magnetic bead technology, yielding genomic, bacterial and viral DNA ready for use in PCR and other downstream applications.

Designed for use with the automated DiaSorin LIAISON Ixt/Arrow instruments, the kits perform with high reproducibility. They have been shown to yield high-quality DNA with low occurrence of PCR inhibitory substances. By automating the purification and DNA extraction process, the kits reduce technician hands-on time and increase sample throughput. They are fast and easy to set up, with all reagents required present in the prefilled cartridges, yielding purified DNA from up to 12 faecal samples at a time in less than 50 min.

Related News

Blood-based biomarker can detect sleep deprivation

The biomarker detected whether individuals had been awake for 24 hours with a 99.2% probability...

Epigenetic signature helps to diagnose rare breast tumour

The current way of diagnosing phyllodes tumours is to analyse their cellular features under a...

New instrument measures cardiovascular disease biomarkers

CVD-21 enables a 'liquid cardiovascular biopsy' for quantification of multiple...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd